Synairgen (SNG)

 

SNG Share PerformanceMore

52 week high38.00 25/04/16
52 week low12.10 04/01/17
52 week change -5.00 (-20.00%)
4 week volume4,546,291 22/12/16

Media for (SNG)

Presenter: Richard Marsden, CEO
11/11/2014
Presenter: Richard Marsden
07/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 3878U Synairgen plc 17 January 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Synairgen plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or dis...

Holding(s) in Company

RNS Number: 4682M Synairgen plc 13 October 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Synairgen plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or dis...

Synairgen updates on AZD9412

Synairgen (SNG) has confirmed that AstraZeneca has decided to stop the Phase IIa trial for AZD9412 based on an interim ...

FTSE up on airlines, house builders after sluggish start

London stocks shrugged offer an early sour start to be cautiously ahead, with both the blue-chip and mid-cap indices risin...

AZD9412 Clinical Trial Update

RNS Number: 2831M Synairgen plc 12 October 2016 Press release Synairgen plc ('Synairgen' or the 'Company') AZD9412 Clinical Trial Update ~ AstraZeneca to focus on key secondary endpoints with results expected in Q1 2017 ~ Southampton, UK - 12 October 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announced today t...

Broker Forecast - N+1 Singer issues a broker note on Synairgen PLC

N+1 Singer today reaffirms its buy investment rating on Synairgen PLC (LON:SNG) and cut its price target to 46p (from 4...

Synairgen widens H1 pretax loss

Synairgen has widened its H1 pretax loss to 1.7m, from a year-earlier loss of 1.0m. Revenue was nil, from 25,000. "We are ve...

Interim results for six months ended 30 June 2016

RNS Number: 5051K Synairgen plc 22 September 2016 Press release Synairgen plc ('Synairgen' or the 'Company') Interim results for the six months ended 30 June 2016 ~ Clinical development of AZD9412 with AstraZeneca on track and Pharmaxis collaboration progressing towards the clinic ~ Southampton, UK - 22 September 2016: Synairgen plc (LSE: SNG), the respir...

Fundamental DataMore

EPS-2.47
Dividend yield0 %

Equity Research (SNG)

edison investment research
Synairgen
14/07/2014
The recent exclusive global deal with AstraZeneca, potentially worth $230m, to in-license SNG001 for the treatment of asthma is a strong validation of Synairgen’s in-vitro cell-based approach using...

Latest discussion posts More

  • GRIFFITHS buying more.

    Follow the smart money. Clearly sees massive value. That in itself is a reason to buy.
    17-Jan-2017
    Disorder
  • Interest.

    Still muted interest and total trades still less than 1/2mil Walked down over the months much to viciously. A slight market correction underway, but still a long way to go to ...
    17-Jan-2017
    Disorder
  • Reiterated #1.37 Price Target

    Synairgen had its ?Corporate? rating reiterated by analysts at FinnCap. They now have a GBP 137.00p price target on the stock. The share price of Synairgen (LON:SNG) was ...
    16-Jan-2017
    Disorder

Users' HoldingsMore

Users who hold Synairgen also hold..
PREMIER OIL23%
ID:ISIN:VGG9828A119420%
SIRIUS MINERALS16%
ROCKHOPPER16%
VECTURA16%

Codes & Symbols

ISINGB00B0381Z20
SymbolsSNG, LSE:SNG, SNG.L, SNG:LN, LON:SNG, XLON:SNG